Evidence map›Paper›PMID 30126559›Full record

Trial reportJournal of the National Medical Association2018

Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.

L Julian Haywood, Barry R Davis, Linda B Piller, Lara M Simpson, Alokananda Ghosh, Paula T Einhorn, Charles E Ford, Jeffrey L Probstfield, Elsayed Z Soliman, Jackson T Wright and 1 more

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of the National Medical Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

L Julian HaywoodLAC+USC Medical Center, Keck School of Medicine, Los Angeles, CA, USA.
Barry R DavisCoordinating Center for Clinical Trials, The University of Texas School of Public Health, Houston, TX, USA.
Linda B PillerCoordinating Center for Clinical Trials, The University of Texas School of Public Health, Houston, TX, USA. Electronic address: Linda.B.Piller@uth.tmc.edu.
Lara M SimpsonCoordinating Center for Clinical Trials, The University of Texas School of Public Health, Houston, TX, USA.
Alokananda GhoshCoordinating Center for Clinical Trials, The University of Texas School of Public Health, Houston, TX, USA.
Paula T EinhornDivision of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD, USA.
Charles E FordCoordinating Center for Clinical Trials, The University of Texas School of Public Health, Houston, TX, USA.
Jeffrey L ProbstfieldClinical Trials Service Unit, University of Washington, Seattle, WA, USA.
Elsayed Z SolimanEpidemiological Cardiology Research Center (EPICARE), Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Jackson T WrightW T Dahms Clinical Research Unit, University Hospitals Case Medical Center, Cleveland, OH, USA.
ALLHAT Collaborative Research Group
LAC+USC Medical Center · USNational Heart Lung and Blood Institute · USUniversity Hospitals Case Medical Center · USUniversity of Washington · USWake Forest University · US

Funding

CLINICAL TRIALS CENTER FOR ALLHAT-N01HC35130-268035130N01HC035130 · HC · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · 1993 to 2005
$6.3M
NHLBI NIH HHS HHSN268201100036CNHLBI NIH HHS N01 HC035130
6 · The paper itself

Abstract

BACKGROUND AND

aimsALLHAT, a randomized, double-blind, active-controlled, multicenter clinical trial of high risk hypertensive participants, compared treatment with an ACE-inhibitor (lisinopril) or calcium channel blocker (amlodipine) with a diuretic (chlorthalidone). Primary outcome was the occurrence of fatal coronary heart disease or nonfatal myocardial infarction. For this report, post-hoc analyses were conducted to determine the contribution of baseline characteristics of participants with or without baseline or incident atrial fibrillation (AF) and atrial flutter (AFL) to stroke, heart failure (HF), coronary heart disease (CHD), and mortality outcomes. METHODS AND

resultsMinnesota Coding of baseline and biennial in-trial ECGs was used to determine the 334 baseline and 537 incident AF/AFL cases, respectively participants with AF/AFL: Cox regression was used to estimate hazard ratios of presence versus absence of either baseline or incident AF/AFL (as time-dependent covariate) for occurrence of stroke, CHD, HF, or mortality, while adjusting for selected baseline characteristics. Adjusted Cox regression was used to obtain hazard ratios (HRs) for presence versus absence of selected baseline characteristics among those with and without either baseline or incident AF/AFL. After adjusting for baseline characteristics, baseline AF/AFL was associated with stroke, HF, and mortality (HRs [95% CIs] 3.18, [2.34-4.33]; 2.65 [2.02-3.49]; and 2.10 [CI, 1.73-2.55], respectively, P < 0.05). Incident AF/AFL was a significant risk factor for HF and mortality (HRs 2.80 and 2.06, respectively, P < 0.05). Risk factor profiles for clinical outcomes for those with and without baseline or incident AF/AFL were largely similar.

conclusionsAF/AFL is a significant risk factor for stroke, HF, and mortality. Additional risk factors for these outcomes were generally similar for participants with and without baseline or incident AF/AFL.

Indexed as

AgedAged, 80 and overAmlodipineAntihypertensive AgentsAtrial FibrillationAtrial FlutterChlorthalidoneCoronary DiseaseDouble-Blind MethodFemaleHeart FailureHumansHypertensionLisinoprilMaleMyocardial InfarctionAmlodipineAntihypertensive AgentsChlorthalidoneLisinoprilAtrial fibrillationFatal CHDHeart failureHypertensionStroke

Identifiers

PMID30126559
PMCPMC6108439
OpenAlexW2739279375

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.